サルコペニア治療市場：治療タイプ、投与経路、エンドユーザー、地域別、2026年～2032年

サルコペニア治療市場の評価、2026年～2032年

サルコペニアは、筋肉量や筋力を低下させ、高齢者のQOLに深刻な悪影響を及ぼす疾患です。高齢化が進むにつれ、サルコペニアの健康への悪影響や早期発見・早期管理の重要性に関する知識の高まりから、効果的な治療法や介入策への需要が高まっています。Verified Market Researchのアナリストによると、サルコペニア治療市場は、2024年の約2億8,946万米ドルを下回り、予測期間中に4億4,423万米ドルの評価に達すると推定されています。

さらに、継続的な研究開発努力によって新たな治療法が生まれ、医療従事者や患者がこの加齢に関連する病気に対する効果的な治療法を求めているため、市場の拡大が加速しています。これにより、市場は2026年から2032年にかけてCAGR 5.5%で成長することになります。

サルコペニア治療市場定義/概要

サルコペニア治療には、特に高齢者における骨格筋量、筋力、機能の低下を特徴とする変性疾患であるサルコペニアの予防、管理、緩和を目的とした様々な製品とサービスが含まれます。治療戦略には、タンパク質、ビタミン、ミネラルのサプリメントなどの栄養介入、筋力や機能性を改善するためのレジスタンストレーニングや理学療法などが含まれます。サルコペニアの治療は、転倒や骨折のリスクを低下させ、運動能力を向上させ、関連する代謝障害を管理し、より健康的な加齢をサポートし、日常生活における自立性を維持することで、高齢者の生活の質を改善することができます。

サルコペニア治療市場の成長に影響を与える市場促進要因は何か？

世界の高齢者人口の増加は、サルコペニア治療市場の主要促進要因です。世界保健機関（WHO）によると、2015年から2050年にかけて、世界人口に占める60歳以上の割合は12％から22％へとほぼ倍増します。2050年までに、高齢者の80％が低・中所得国に住むことになります。サルコペニアは主に高齢者に発症するため、この人口動態の変化は極めて重要です。国際骨粗鬆症財団によると、サルコペニアは60歳以上の約10％が罹患し、その頻度は80歳以上で50％に増加します。

慢性疾患はサルコペニアを引き起こしたり、悪化させたりするため、治療の必要性が高まる。米国疾病予防管理センター（CDC）によると、米国では10人に6人が少なくとも1つの慢性疾患を抱えており、10人に4人は2つ以上の慢性疾患を抱えています。全世界で約4億6,300万人の成人が罹患している糖尿病は、筋肉の減少を早める可能性があります。研究によると、サルコペニアは2型糖尿病患者において、そうでない人に比べて15％多く見られるといいます。

さらに、医療従事者の意識の高まりと、より優れた診断ツールの開発が、サルコペニア治療市場を推進しています。2018年、European Working Group on Sarcopenia in Older People（EWGSOP）はサルコペニアの定義と診断基準を修正し、その結果、より正確な同定が可能になりました。Journal of Cachexia, Sarcopenia and Muscleに掲載された研究によると、元の基準の代わりに更新されたEWGSOP2基準を使用した場合、サルコペニアの有病率は12.9％から17.7％に増加しました。この診断の強化により、サルコペニア治療の需要が増加すると予測されます。

サルコペニア治療の導入に伴う主な課題は何か？

サルコペニア治療や療法には高額な費用がかかるため、市場にとって大きな課題となっています。栄養補助食品や専門医による医薬品など、多くの効果的な治療法は法外に高価であるため、高齢者人口の大部分には手が届かないです。この経済的障壁は、患者が治療を求めたり、処方されたレジメンを守ったりする意欲を失わせ、サルコペニア治療の全体的な有効性を低下させ、市場の拡大を制限しています。

さらに、加齢に伴う社会的信条や偏見が治療の障壁となっています。多くの人がサルコペニアの治療を受けることをためらっているが、これは加齢に対する誤解や、筋肉が減少するのは年をとる上で避けられないことであるという考えによるものです。このため、サルコペニアに取り組む必要性が理解されず、過小診断や過小治療につながり、市場の成長可能性を制限しています。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 主な調査結果
• 市場概要
• 市場ハイライト

第3章 市場概要

• 市場規模と成長の可能性
• 市場動向
• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析

第4章 サルコペニア治療市場：治療タイプ別

• タンパク質サプリメント
• ビタミンB12サプリメント
• ビタミンDとカルシウムのサプリメント
• その他

第5章 サルコペニア治療市場：投与経路別

• 経口
• 注射剤
• その他

第6章 サルコペニア治療市場：エンドユーザー別

• 病院
• ドラッグストアおよび小売薬局
• オンライン薬局

第7章 地域別分析

• 北米
• 米国
• カナダ
• メキシコ
• 欧州
• 英国
• ドイツ
• フランス
• イタリア
• アジア太平洋
• 中国
• 日本
• インド
• オーストラリア
• ラテンアメリカ
• ブラジル
• アルゼンチン
• チリ
• 中東・アフリカ
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦

第8章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会
• COVID-19の市場への影響

第9章 競合情勢

• 主要企業
• 市場シェア分析

第10章 企業プロファイル

• Nestle Health Science
• Sanofi S.A.
• Bayer AG
• Haleon Group of Companies
• Novartis AG
• Abbott Laboratories
• Metagenics LLC
• Pfizer Inc.
• GlaxoSmithKline plc.
• Makers Nutrition LLC

第11章 市場の展望と機会

• 新興技術
• 今後の市場動向
• 投資機会

第12章 付録

• 略語リスト
• 出典と参考文献

Sarcopenia Treatment Market Valuation - 2026-2032

The world's aging population is the main factor driving the sarcopenia treatment market since it raises the prevalence of the ailment, which lowers muscle mass and strength and has a serious negative impact on the quality of life for the elderly. As more people age, the demand for effective therapies and interventions grows, driven by increased knowledge of sarcopenia's negative health impacts and the importance of early detection and management. According to the analyst from Verified Market Research, the sarcopenia treatment market is estimated to reach a valuation of USD 444.23 Million over the forecast subjugating around USD 289.46 Million valued in 2024.

Furthermore, continuing research and development efforts are yielding new therapeutic alternatives, accelerating market expansion as healthcare practitioners and patients seek effective treatments for this age-related illness. It enables the market to grow at a CAGR of 5.5% from 2026 to 2032.

Sarcopenia Treatment Market: Definition/Overview

Sarcopenia treatment includes a variety of products and services aimed at preventing, managing, or alleviating sarcopenia, a degenerative disorder characterized by the loss of skeletal muscle mass, strength, and function, especially in older persons. Treatment strategies include nutritional interventions, such as protein, vitamin, and mineral supplements, as well as resistance training and physical therapies to improve muscular strength and functionality. Sarcopenia treatment can improve the quality of life for the aged by lowering the risk of falls and fractures, increasing mobility, managing associated metabolic disorders, supporting healthier aging, and preserving independence in everyday activities.

What are the Drivers Influencing the Growth of the Sarcopenia Treatment Market?

The growing older population worldwide is a major driver of the sarcopenia treatment market. According to the World Health Organization (WHO), the proportion of the global population over the age of 60 will nearly double between 2015 and 2050, from 12% to 22%. By 2050, 80% of the elderly will live in low- and middle-income countries. This demographic shift is critical since sarcopenia primarily affects elderly people. According to the International Osteoporosis Foundation, sarcopenia affects about 10% of those over the age of 60, with the frequency increasing to 50% in those over the age of 80.

Chronic conditions lead to or aggravate sarcopenia, increasing the need for treatment. According to the Centers for Disease Control and Prevention (CDC), 6 in 10 persons in the United States have at least one chronic disease, with 4 in 10 having two or more. Diabetes, which affects around 463 million adults globally, can speed up muscle loss. Sarcopenia is 15% more common in persons with type 2 diabetes than in those without the disease, according to studies.

Furthermore, the growing awareness among healthcare professionals and the development of better diagnostic tools are propelling the sarcopenia treatment market. In 2018, the European Working Group on Sarcopenia in Older People (EWGSOP) modified its definition and diagnostic criteria for sarcopenia, resulting in more accurate identification of the condition. According to a study published in the Journal of Cachexia, Sarcopenia and Muscle, the prevalence of sarcopenia increased from 12.9% to 17.7% when the updated EWGSOP2 criteria were used instead of the original criteria. This enhanced diagnosis is projected to increase the demand for sarcopenia treatments.

What are the Key Challenges Associated with Adopting Sarcopenia Treatment?

The high expense of sarcopenia treatment and therapies presents a significant challenge for the market. Many effective therapies, such as nutritional supplements and specialist pharmaceuticals, are prohibitively expensive, making them inaccessible to a large percentage of the senior population. This financial barrier discouraged patients from seeking treatment or sticking to prescribed regimens, reducing the overall effectiveness of sarcopenia care and restricting market expansion.

Furthermore, social beliefs and stigmas associated with aging serve as a barrier to treatment. Many people are hesitant to seek treatment for sarcopenia because of misconceptions about aging and the belief that muscle loss is an unavoidable part of growing older. This hesitation leads to underdiagnosis and undertreatment, as those affected fail to grasp the need to tackle sarcopenia, limiting the market's growth potential.

Category-wise Acumens

How Does the Dominance of the Vitamin D & Calcium Supplements Segment Propel the Market?

According to VMR analyst, the vitamin D & calcium supplement segment is anticipated to dominate the segment within the sarcopenia treatment market during the forecast period. The importance of Vitamin D in muscular health adds greatly to the segment's prominence. Vitamin D is required for calcium absorption and bone metabolism, which are critical for muscular function. According to research, adequate levels of Vitamin D can help minimize the incidence of sarcopenia, especially in older persons, resulting in growing demand for these supplements as muscle loss prevention strategies.

The increasing knowledge of sarcopenia's negative effects on health is another driver of the market. As more people become aware of the problems connected with muscle loss, there is a greater emphasis on nutritional solutions to counteract the condition. Vitamin D and calcium supplements are highlighted in educational efforts directed at older persons, driving their usage as part of a proactive strategy to preserve muscle strength and overall health.

Furthermore, the rising prevalence of Vitamin D deficiency among the elderly is a major factor driving demand for Vitamin D and calcium supplements. Many older persons have low Vitamin D levels because of restricted sun exposure and nutritional intake, so supplementation is an important technique for preventing sarcopenia. The increased knowledge of deficiency-related hazards has resulted in a spike in demand for these specific supplements as effective treatment options.

How does the Increasing Hospitalization Rates Contribute to the Demand for Hospitals?

The hospital segment is estimated to hold the largest share of the sarcopenia treatment market during the forecast period. The rising hospitalization rates of elderly people experiencing problems from sarcopenia are a major contributing factor. As the population ages, more people may need medical attention for falls, fractures, and other muscle-related health concerns. Hospitals have an important role in delivering complete care, including diagnosis, treatment, and rehabilitation, which increases the demand for sarcopenia treatments in these settings.

Hospitals' domination is further aided by the availability of specialized healthcare professionals and resources. Hospitals have interdisciplinary teams of geriatricians, dietitians, and physical therapists who can work together to meet the complicated needs of sarcopenic patients. This comprehensive strategy improves treatment efficacy and patient outcomes, making hospitals the optimal setting for managing sarcopenia.

Furthermore, insurance coverage and reimbursement policies frequently favor hospital-based therapies, making them more accessible for patients. Many health insurance policies offer better coverage for hospital-administered treatments than those bought from pharmacy stores or online pharmacies. This financial incentive encourages patients to seek therapy in hospitals, reinforcing the hospital segment's dominant position in the sarcopenia treatment market.

Country/Region-wise Acumens

How Does the High Prevalence of Chronic Diseases Associated with Sarcopenia in Asia Pacific Propel the Market?

According to VMR analysis, the Asia Pacific region is estimated to dominate in sarcopenia treatment market during the forecast period. The Asia Pacific area has a high prevalence of chronic diseases related to sarcopenia, which drives the market. According to the International Diabetes Federation, the Western Pacific region (which comprises the majority of East Asia and Oceania) had the highest number of diabetic adults (163 million) in 2019. This number is predicted to increase to 212 million by 2045. Diabetes is known to accelerate muscle loss, with research indicating that the prevalence of sarcopenia in Asian people with type 2 diabetes is approximately 14.8%, which is much greater than in non-diabetic persons.

Furthermore, the growing healthcare spending and improved diagnostic capabilities in the Asia Pacific region are propelling the sarcopenia treatment market. According to the World Bank, health spending per capita in East Asia and the Pacific rose from $571 in 2010 to $937 in 2019, showing a growing investment in healthcare. In China, one of the region's largest marketplaces, health spending per capita has more than doubled, from $289 in 2010 to $731 in 2019. This increased funding allows for better detection and treatment of illnesses such as sarcopenia.

What are the Drivers Bolstering the Sarcopenia Treatment Market in North America?

North America is estimated to exhibit substantial growth within the market during the forecast period. North America has a huge and expanding older population, which drives the sarcopenia treatment market. According to the United States Census Bureau, the number of Americans aged 65 and up is expected to nearly double, from 52 million in 2018 to 95 million by 2060. Sarcopenia is highly prevalent in North America. According to a study published in the Journal of Cachexia, Sarcopenia, and Muscle, the prevalence of sarcopenia in the United States varies between 10% and 40% among persons aged 60 and older, depending on the diagnostic criteria utilized. This high frequency indicates a sizable market for sarcopenia treatments.

Furthermore, North America, particularly the United States, has high rates of obesity and accompanying metabolic problems, which are directly tied to sarcopenia. According to the Centers for Disease Control and Prevention (CDC), the obesity prevalence in the United States was 42.4% in 2017-2018. According to data from the National Health and Nutrition Examination Survey (NHANES), the prevalence of sarcopenic obesity among older persons in the United States ranges from 4% to 25%, depending on the definition. The increased incidence of obesity, particularly sarcopenic obesity, is driving the need for comprehensive sarcopenia treatments that target both muscle loss and metabolic health.

Competitive Landscape

The sarcopenia treatment market is competitive, with several significant competitors contending for market share. Large companies are focusing on strategic initiatives such as new product launches, mergers and acquisitions, and research and development efforts to increase their market position.

Some of the prominent players operating in the sarcopenia treatment market include:

Nestle Health Science

Sanofi S.A.

Bayer AG

Haleon Group of Companies

Novartis AG

Abbott Laboratories

Metagenics LLC

Pfizer, Inc.

GlaxoSmithKline plc.

Makers Nutrition LLC

Latest Developments:

In July 2024, Abbott Laboratories launched clinical research to assess the efficacy of its novel protein supplement designed exclusively for sarcopenia sufferers. The study's goal is to examine improvements in muscle strength and functionality among older persons, reinforcing Abbott's emphasis on new solutions to age-related health issues.

In June 2024, Pfizer Inc. announced a collaboration with various academic institutions to enhance sarcopenia research. This collaboration intends to investigate the potential of new pharmacological therapy paired with nutritional interventions, demonstrating Pfizer's commitment to addressing the growing concerns about muscle loss in the elderly population.

Sarcopenia Treatment Market, by Category

Treatment Type:

Protein Supplements

Vitamin B12 Supplements

Vitamin D & Calcium Supplements

Others

Route of Administration:

Oral

Injectable

Others

End-User:

Hospitals

Drug Stores and Retail Pharmacies

Online Pharmacies

Region:

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Sarcopenia Treatment Market, By Treatment Type

• Protein Supplements
• Vitamin B12 Supplements
• Vitamin D & Calcium Supplements
• Others

5. Sarcopenia Treatment Market, By Route of Administration

• Oral
• Injectable
• Others

6. Sarcopenia Treatment Market, By End-User

• Hospitals
• Drug Stores and Retail Pharmacies
• Online Pharmacies

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Nestle Health Science
• Sanofi S.A.
• Bayer AG
• Haleon Group of Companies
• Novartis AG
• Abbott Laboratories
• Metagenics LLC
• Pfizer Inc.
• GlaxoSmithKline plc.
• Makers Nutrition LLC

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References